Xention grants Servier option to AF compound, XEN-D0103

Xention Ltd. (Cambridge, U.K.) granted Servier (Neuilly-sur-Seine, France) an option to acquire rights to develop and commercialize atrial fibrillation (AF) compound XEN-D0103, excluding the U.S. and ...